Absci Corporation reported Q2 earnings on August 11 into a week that combined a sharp short interest rebuild, a 11% price gain, and uniform analyst reaffirmation — a tension between rising bearish positioning and bullish price action that defines the setup heading into the post-print period.
Short interest is the clearest story this week, and it tells a cautionary tale. Shorts rebuilt aggressively on August 10-11, pushing SI from roughly 33.4 million shares to 36.3 million — a jump of around 8.7% in a single session, now representing 24.1% of the free float. That is a meaningful level for a pre-profitability biotech. Yet the borrow market is not flashing distress. Availability is running at 270% — meaning nearly three shares remain available to borrow for every one already lent out — a loose condition by any measure, and a dramatic loosening from the sub-100% availability readings seen in early July. Cost to borrow remains low at 0.49%, up 14% on the week but well below the 1.24% peak hit in early July. The combination tells a specific story: shorts are adding exposure, but the lending pool is accommodating them easily, and there is no squeeze pressure building in the near term. Options positioning confirms the lack of urgency. The put/call ratio is nearly identical to its 20-day average at 0.135, essentially flat on a z-score basis, and far below the 52-week high of 0.40. Options traders are not rushing for downside protection.
The Street is uniformly bullish but measured. Needham and BTIG both reiterated Buy ratings on August 12 — the day after earnings — holding targets at $11 and $13 respectively. Those targets imply 17% to 38% upside from the $9.41 close, but both sit below the broader analyst consensus mean of $13.89. Truist raised its target to $17 in early July, and Guggenheim, HC Wainwright, and Leerink all carried Buy or Outperform ratings with targets in the $12-$17 range following a wave of upgrades in June. The bull case rests on ABS-201 clinical data de-risking the pipeline and the potential for a proof-of-concept inflection in 2026 toward a modelled peak revenue of $501 million by 2036. The bear case is blunt: every program is early-stage, the company is loss-making (PE sits at -13.8x, EV/EBITDA at -12.3x), and clinical risk is unresolved. The ORTEX short score is elevated at 68.9, ranking in the 15th percentile on short score rank — meaning 85% of the universe carries less short-side pressure.
Institutional flows add an interesting layer. ARK Investment Management holds 8.1% of shares and added nearly 1.9 million shares through July — a meaningful conviction top-up from a firm whose ownership signals tend to attract attention in momentum-driven biotech names. BlackRock added 920,000 shares and State Street 772,000 over the same period. Founder and CEO Sean McClain sold 59,896 shares in late June at $10.08 for around $603,000, reducing his reported stake — a routine post-rally trim at a price close to today's level, though worth noting given the 90-day insider net remains marginally positive at roughly $1 million across all insiders. A director, Mary Szela, bought $149,000 worth in late June at $11.54, slightly above current prices.
Among peers, the week's price action was broadly positive. FDMT gained 11.8% on the week and NTRA rose 13.6%, both outpacing ABSI's 11%. RXRX — Recursion Pharmaceuticals, the closest AI-drug-discovery comparable — gained just 1.2%, making ABSI's move look more idiosyncratic than sector-wide. BEAM fell 5.3%, reinforcing that gene-editing names are not sharing the same tailwind.
The next data point worth tracking is the clinical readout cadence for ABS-201 — the stock has moved on ABS-201 news before, with an 8.6% single-day gain logged on August 7, and the bull-bear debate will sharpen or soften entirely around what that data shows when it surfaces.
See the live data behind this article on ORTEX.
Open ABSI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
